Research progress of xanthine oxidoreductase in biological functions and its inhibitor development

Abstract

Abstract: xanthine oxidoreductase(XOR)is a member of the molybdoenzyme family and best known for its catalytic role in purine degradation , metabolizing hypoxanthine and xanthine to uric acid with concomitant generation of superoxide and hydrogen peroxide.In addition to its role in the pathophysiology of hyperuricaemia and gout , the role for XOR beyond purine metabolism was first suggested in ischaemia-reperfusion injury , there is growing evidence that it also participates in endothelial dysfunction,hypertension and heart failure.Importantly , the XOR inhibitor attenuates dysfunction especially in heart failure caused by XOR in these disease states.Attention to the broader range of XOR bioactivity in the cardiovascular system has prompted strong interest based XOR drug development by pharmaceuticals company.

Key words: xanthine oxidoreductase, reactive oxygen species, ischaemia-reperfusion injury, heart failure, drug development

CLC Number:

ZHU Shen-yin, ZHOU Yuan-da, DU Guan-hua. Research progress of xanthine oxidoreductase in biological functions and its inhibitor development[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(10): 1081-1086.

References

1 Harrison R.Structure and function of xanthine oxidoreductase:where are we now[J] ?Free Radic BiolMed, 2002;33:774-97
2 Berry CE, Hare JM.Xanthine oxidoreductase and cardiovascular disease:molecular mechanisms and pathophysiological implications[J].J Physiol, 2004;555:589-606
3 Xu P, Huecksteadt TP, Hoidal JR.Molecular cloning and characterization of the human xanthine dehydrogenase gene (XDH)[J].Genomics, 1996;34:173-80
4 McManaman JL, Bain DL.Structural and conformational analysis of the oxidase to dehydrogenase conversion of xanthine oxidoreductase[J].J Biol Chem , 2002;277:21261-8
5 Maia L, Vala A, Mira L.NADH oxidase activity of rat liver xanthine dehydrogenase and xanthine oxidase-contribution for damage mechanisms[J].Free Radic Res, 2005;39:979-86
6 Li H, Samouilov A, Liu X, Zweier JL.Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrate reduction:evaluation of its role in nitrite and nitric oxide generation in anoxic tissues[J].Biochemistry , 2003;42:1150-9
7 Millar TM.Peroxynitrite formation from the simultaneous reduction of nitrite and oxygen by xanthine oxidase[J].FEBS Lett,2004;562:129-33
8 Pritsos CA.Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system[J].Chem Biol Interact,2000;129:195-208
9 Nishino T, Okamoto K, Kawaguchi Y, Hori H, Matsumura T,Eger BT, et al.Mechanism of the conversion of xanthine dehydrogenase to xanthine oxidase:identification of the two cysteine disulfide bonds and crystal structure of a non-convertible Chin J Clin Pharmacol Ther 2006 Oct;11(10) rat liver xanthine dehydrogenase mutant[J].J Biol Chem ,2005;280:24888-94
10 Angelos MG, Kutala VK, Torres CA, He G, Stoner JD, Mohammad M, et al.Hypoxic reperfusion of the ischemic heart and oxygen radical generation[J].Am J Physiol Heart Circ Physiol, 2006;290:H341-7
11 Choi HK, Mount DB, Reginato AM.Pathogenesis of gout[J].Ann InternMed, 2005;143:499-516
12 Zalba G, Beaumont J, San Jose G, Fortuno A, Fortuno MA,Diez J.Vascular oxidant stress:molecular mechanisms and pathophysiological implications[J].J Physiol Biochem , 2000;56:57-64
13 Houston M, Estevez A, Chumley P, Aslan M, Marklund S,Parks DA, et al.Binding of xanthine oxidase to vascular endothelium.Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling[J].J Biol Chem, 1999;274:4985-94
14 Patetsios P, Song M, Shutze WP, Pappas C, Rodino W,Ramirez JA, et al.Identification of uric acid and xanthine oxidase in atherosclerotic plaque[J].Am J Cardiol, 2001;88:188-91
15 Laakso J, Mervaala E, Himberg JJ, Teravainen TL, Karppanen H, Vapaatalo H, et al.Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension[J].Hypertension,1998;32:902-6
16 Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C,Mu W, et al.Hyperuricemia induces endothelial dy sfunction[J].Kidney Int , 2005;67:1739-42
17 Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R,Kohler C, et al.vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure:role of xanthineoxidase and extracellular superoxide dismutase[J].Circulation ,2002;106:3073-8
18 de Jong JW, Schoemaker RG, de Jonge R, Bernocchi P, Keijzer E, Harrison R, et al.Enhanced expression and activity of xanthine oxidoreductase in the failing heart[J].J Mol Cell Cardiol, 2000;32:2083-9
19 Mellin V, Isabelle M, Oudot A, Vergely-Vandriesse C,Monteil C, Di Meglio B, et al.Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure[J].Eur Heart J ,2005;26:1544-50
20 Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, et al.Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart[J].Circ Res, 2002;90:297-304
21 Kinugasa Y, Ogino K, Furuse Y, Shiomi T, Tsutsui H,Yamamoto T, et al.Allopurinol improves cardiac dy sfunction after ischemia-reperfusion via reduction of oxidative stress in isolated perfused rat hearts[J].Circ J , 2003;67:781-7
22 GuanW, Osanai T, Kamada T, Hanada H, Ishizaka H, Onodera H, et al.Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction[J].J Cardiovasc Pharmacol, 2003 , 41:699-705
23 Kogler H, Fraser H, McCune S, Altschuld R, Marban E.Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium[J].Cardiovasc Res, 2003;59:582-92
24 Amado LC, Saliaris AP, Raju SV, Lehrke S, St John M, Xie J, et al.Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure[J].JMol Cell Cardiol, 2005;39:531-6
25 Duncan JG, Ravi R, Stull LB, Murphy AM.Chronic xanthine oxidase inhibition prevents myofibrillar protein oxidation and preserves cardiac function in a transgenic mouse model of cardiomyopathy[J].Am J Physiol Heart Circ Physiol , 2005;289:H1512-8
26 Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD.Allopurinol improves endothelial dysfunction in chronic heart failure[J].Circulation, 2002;106:221-6
27 Kittleson MM, Hare JM.Xanthine oxidase inhibitors:an emerging class of drugs for heart failure[J].Eur Heart J, 2005;26:1458-60
28 Freudenberger RS, Schwarz RPJr, Brown J, Moore A, Mann D, GivertzMM, et al.Rationale , design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III-IV congestive heart failure[J].Expert Opin Investig Drugs , 2004;13:1509-16
29 Becker MA, Schumacher HR, Wortmann RL, MacDonald PA,Palo WA, Eustace D, et al.Febuxostat , a novel nonpurine selective inhibitor of xanthine oxidase:a twenty-eight-day , multicenter , phase II , randomized, double-blind, placebo-controlled,dose-response clinical trial examining safety and efficacy in patients with gout[J].Arthritis Rheum , 2005;52:916-23
30 Zhu JX, Wang Y, Kong LD, Yang C, Zhang X.Effects of Biota orientalis extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver[J].J Ethnopharmacol, 2004;93:133-40
31 Yu Z, Fong WP, Cheng CH.The dual actions of morin (3 , 5,7, 2', 4'-pentahydroxyflavone)as a hypouricemic agent:uricosuric effect and xanthine oxidase inhibitory activity[J].J Pharmacol ExPTher , 2006;316:169-75
32 Wang Y, Zhu JX, Kong LD, Yang C, Cheng CH, Zhang X.Administration of procyanidins from grape seeds reduces serum uric acid levels and decreases hepatic xanthine dehydrogenase oxidase activities in oxonate-treated mice[J].Basic Clin Pharmacol Toxicol, 2004;94:232-7
33 Yoshizumi K, Nishioka N, Tsuji T.Xanthine oxidase inhibitory activity and hypouricemia effect of propolis in rats[J].Yakugaku Zasshi, 2005;125:315-21
34 Kong LD, Cai Y, Huang WW, Cheng CH, Tan RX.Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout[J].J Ethnopharmacol , 2000;73:199-207

[1]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[2]	MA Guangli, ZHANG Jing. Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
[3]	PENG Yong, FAN Jianfeng, XIONG Xuhua, XIAO Dongping, GAO Zhaobo, ZHENG Chunhua. Effect of iron dextran dispersible tablets on heart failure patients with iron deficiency [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 178-183.
[4]	CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
[5]	YANG Sheng, WANG Deguo. Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
[6]	WANG Yali, HUO Xulei, CHEN Feng, LI Shenglan, ZHENG Xiaohong, WANG Can, LI Wenbin. Research progress on the antitumor effect of nifurtimox [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 955-960.
[7]	PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng. Progress of pharmacotherapy for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381.
[8]	LI Wenxia, FANG Liuyuan, QIAN Shenxian. Mechanism of ferroptosis and its research progress in lymphoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 314-321.
[9]	LIU Ping, QIU Bo, WU Huizhen. Pharmacology and clinical evaluation of vericiguat in the treatment of heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 212-218.
[10]	LIU Wei, XUE Junsheng, YU Zhiheng, WANG Ziyu, CHEN Rong, ZHOU Tianyan. Interpretation of pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer guidance for industry [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 86-94.
[11]	GAO Lili, CHEN Rui, LI Lujin, ZHENG Qingshan . Dose selection of obeticholic acid in hepatic impairment patients and the review consideration of FDA [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 760-767.
[12]	XU Yonghua, SHI Xianghong. Analysis of the efficacy of torasemide combined with levocarnitine in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 647-652.
[13]	SUN Bo, FU Shujun, CHEN Guiliang, LI Li. Applications of Drug Interaction Study in New Drug Development and Regulartory Decision-making [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1095-1102.
[14]	ZHANG Yulong, ZHAO Ying, ZHANG Wei. Application of pharmacomicrobiomics in new drug development [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 58-64.
[15]	CHEN Lifang, WANG Bo, WANG Weirong. Research advances of histone deacetylase 3 in cardiovascular diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 88-97.